Imago Biosciences, Inc.

Ferrokin Biosciences, Inc.

Hugh Young Rienhoff, Jr

Michael John Clare

Amy E Tapper

John Michael McCall

Cassandra Celatka

Stephan D Parent

Patricia Andres

Jason A Hanko

Huamin Zhang

The present disclosure relates to compounds and methods which may be useful as inhibitors of KDM1A for the treatment or prevention of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation in cancer cells in a human or animal subject are also provided for treatment of disease such as acute myelogenous leukemia.

KDM1A inhibitors for the treatment of disease

Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.

Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDMIA, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.

The present invention provides, among other things, effective oral formulations based on desazadesferrithiocin polyether (DADFT-PE) analogs, salts and polymorphs thereof, as well as their application for treatment of metal overload, in particular, iron overload, and associated diseases, disorders and conditions.

Oral formulations for treating metal overload

Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogs, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.

Salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents

Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.

Growing community of inventors

San Carlos, CA, United States of America

Hugh Young Rienhoff, Jr